Highlights

• Chimeric Therapeutics dosed the first patient in its Phase 1/2 clinical trial for CHM CDH17 CAR-T cell therapy.
• In September, Chimeric announced collaboration with Achieve Clinics to expand access to CHM CDH17 through Achieve’s PRO-Aph™ process.
• The company formed a partnership with Cell Therapies Pty Ltd to explore the manufacturing of its CAR T-cell therapies in Australia.
• Chimeric’s CHM CORE-NK Phase 1b combination trial reported a complete response in an acute myeloid leukemia patient.

Chimeric Therapeutics Limited (ASX:CHM) achieved significant milestones in the September 2024 quarter, including the enrollment and dosing of the first patient in the CHM CDH17 Phase 1/2 trial. This trial aims to guide dose selection, with plans for Phase 2 expansion targeting specific cancer cohorts.

Chimeric also expanded the patient access to CHM CDH17 through a partnership with Achieve Clinics and teamed up with Cell Therapies Pty Ltd to explore CAR T cell manufacturing in Australia.

Phase 1/2 Trial for CHM CDH17 CAR-T Advances

In August, Chimeric Therapeutics dosed the first patient in its Phase 1/2 clinical trial for CHM CDH17 CAR-T cell therapy at the Sarah Cannon Research Institute in Nashville, Tennessee. This trial is enrolling patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours at multiple US cancer centres.

The University of Pennsylvania (Penn) also began enrolling patients for the trial, with additional sites anticipated to open by the end of 2024.

In September, the company announced a collaboration with Achieve Clinics to expand access to CHM CDH17 through Achieve’s PRO-Aph™ process, which is expected to improve cell collection early in the cancer treatment process and enhance patient recruitment and trial timelines.

Chimeric Partners with Cell Therapies

Chimeric Therapeutics has announced a strategic partnership with Cell Therapies Pty Ltd to explore the manufacturing of its CAR T-cell therapies in Australia.  This collaboration aims to provide Australian patients with access to Chimeric’s cutting-edge clinical trials, focused on cancer treatment through CAR T and NK cell therapies. With four clinical trials currently underway in the US, Chimeric is also considering the addition of Australian sites to broaden patient access.

Post-quarter, Chimeric reported a notable achievement in its CHM CORE-NK Phase 1b combination trial: an Acute Myeloid Leukemia (AML) patient achieved a complete response. Additionally, the company secured commitments for a AU$5 million capital raise.

Chimeric also received AU$1.56 million from Endpoints Capital, under a facility linked to the company’s anticipated FY24 Research and Development Tax Incentive (RDTI). The funds will support the clinical trial pipeline.

The share price of CHM was AU$0.010 as on 11 November 2024.